• Ching-Chi Chi, Yen-Wen Wu, Ting-Hsing Chao, Chih-Chiang Chen, Yi-Ju Chen, Hao-Min Cheng, Hsien-Yi Chiu, Yu-Wei Chiu, Wen-Hung Chung, Tsu-Yi Hsieh, Po-Hsun Huang, Yu-Huei Huang, Shang-Hung Lin, Tsung-Hsien Lin, Kwo-Chang Ueng, Chun-Chieh Wang, Yu-Chen Wang, Nan-Lin Wu, Jia-Yin HouCharlesCDepartment of Medicine, MacKay Medical College, New Taipei City, Taiwan; Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: jiayinhou@gmail.com., and Tsen-Fang Tsai.
• Department of Dermatology, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
• J Formos Med Assoc. 2023 Jun 1; 122 (6): 442457442-457.

AbstractPsoriatic disease is a chronic inflammatory disorder with skin and joint manifestations. Due to the persistent inflammatory state exhibited by patients with psoriasis, multiple systemic comorbidities occur more frequently in patients with psoriasis than in the general population, and the risk of cardiovascular (CV) diseases is significantly increased. As the pathophysiology of psoriatic disease is becoming better understood, the sharing of underlying pathogenic mechanisms between psoriatic and CV diseases is becoming increasingly apparent. Consequently, careful attention to CV comorbidities that already exist or may potentially develop is needed in the management of patients with psoriasis, particularly in the screening and primary prevention of CV disease and in treatment selection due to potential drug-drug and drug-disease interactions. Furthermore, as the use of effective biologic therapy and more aggressive oral systemic treatment for psoriatic disease is increasing, consideration of the potential positive and negative effects of oral and biologic treatment on CV disease is warranted. To improve outcomes and quality of care for patients with psoriasis, the Taiwanese Dermatological Association, the Taiwanese Association for Psoriasis and Skin Immunology, and the Taiwan Society of Cardiology established a Task Force of 20 clinicians from the fields of dermatology, cardiology, and rheumatology to jointly develop consensus expert recommendations for the management of patients with psoriatic disease with attention to CV comorbidities.Copyright © 2022 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

18 keywords...

hide…